The neuregulins (NRGs) are members of the epidermal growth factor (EGF) family of peptide growth factors. These hormones are agonists for the ErbB family of receptor tyrosine kinases, a family that includes the epidermal growth factor receptor (EGFR/ErbB1), ErbB2/ Neu/HER2, ErbB3/HER3, and ErbB4/HER4. We recently observed that the EGF family hormone NRG2b is a potent agonist for ErbB4. In contrast, NRG2a, a splicing isoform of the same gene that encodes NRG2b, is a poor ErbB4 agonist. We hypothesized that carboxyl-terminal residues of NRG2b are critical for stimulation of ErbB4 tyrosine phosphorylation and coupling to downstream signaling events. Here, we demonstrate that the substitution of a lysine residue for Phe45 in NRG2b results in reduced ligand potency. We also demonstrate that substitution of a phenylalanine for Lys45 in NRG2a results in increased ligand potency. Finally, analyses of the gain-of-function NRG2a Chg5 mutant demonstrate that Gln43, Met47, Asn49, and Phe50 regulate ligand efficacy. Thus, these data indicate that carboxyl-terminal residues of NRG2b are critical for activation of ErbB4 signaling. Moreover, these NRG2a and NRG2b mutants reveal new insights into models for ligand-induced ErbB family receptor tyrosine phosphorylation and coupling to downstream signaling events.
Introduction
Neuregulins (NRGs) are members of the epidermal growth factor (EGF) family of peptide hormones (reviewed in Buonanno and Fischbach, 2001; Gullick, 2001) , a family that includes EGF itself as well as transforming growth factor alpha (TGFa), betacellulin (BTC), amphiregulin (AR), heparin-binding EGF-like growth factor (HB-EGF), and epiregulin (EPR). NRGs are agonists for the four members of the ErbB family of receptor tyrosine kinases, a family that includes the epidermal growth factor receptor (EGFR/ErbB1), ErbB2/HER2/Neu, ErbB3/HER3, and ErbB4/HER4. There are four NRG genes; at least two of these genes encode multiple ligands through differential transcriptional splicing. Thus, there are more than 10 different NRG isoforms; many of these isoforms display different patterns of ErbB family receptor activation. For example, we recently demonstrated that NRG2b is a potent, direct ErbB4 agonist; in contrast, NRG2a, which is encoded by the same gene as NRG2b, fails to stimulate ErbB4 tyrosine phosphorylation directly (Hobbs et al., 2002) .
Thus, an obvious question is: What is the mechanism underlying the difference in activation of ErbB4 signaling by NRG2a and NRG2b? Here, we demonstrate that Phe45 of NRG2b regulates the potency of this ligand. Moreover, we demonstrate that Gln43, Met47, Asn49, and Phe50 of NRG2b may regulate the efficacy of this ligand. In the discussion, we attempt to put these results in the context of existing models for activation of ErbB family receptor signaling by EGF family hormones. Given these models, we will discuss potential mechanisms by which the carboxyl-terminal amino acids of NRG2b may regulate its activity.
Results

Construction of NRG2 mutants
We have previously reported that NRG2b is a potent agonist for ErbB4 and that NRG2a is not (Hobbs et al., 2002) . Consequently, we hypothesized that there is a domain present in NRG2b and absent in NRG2a that is critical for activation of ErbB4 signaling. A comparison of the sequences of NRG1a, NRG1b, NRG2a, NRG2b, NRG3, and NRG4 suggests that five amino acids near the carboxyl terminus of NRG2b are critical for activation of ErbB4 signaling ( Figure 1 ): Gln43, Phe45, Met47, Asn49, and Phe50. The amount of conservation of these five amino acids in a NRG molecule correlates with stimulation of ErbB4 signaling. We tested this hypothesis by generating five putative loss-of-function NRG2b mutants (Figure 2 ) in which we substituted the corresponding NRG2a residue (Leu43, Lys45, Pro47, Arg49, and Leu50) for one of the five 'critical' residues in NRG2b. These mutants are designated NRG2b Q43L, F45K, M47P, N49R, and F50L. We generated five putative gain-of-function NRG2a mutants by substituting one of the five 'critical' residues in NRG2b for the corresponding residue in NRG2a. These mutants are designated NRG2a L43Q, K45F, P47 M, R49N, and L50F. We also generated a putative gain-offunction NRG2a mutant by substituting all five 'critical residues' in NRG2b for the corresponding residues in NRG2a. This mutant is designated NRG2a Chg5. These mutants were generated by site-directed mutagenesis and were expressed, purified, and quantified as described elsewhere in this report.
The NRG2b F45K mutant is no longer a potent ErbB4 agonist
We first assessed whether any of the putative loss-offunction ErbB4 mutants had lost some of their capacity to stimulate ErbB4 tyrosine phosphorylation. CEM cells, which lack endogenous ErbB family receptor expression, had been previously engineered to express human ErbB4 ectopically, resulting in CEM/ErbB4 cells Riese et al., 1998; Feroz et al., 2002) . We treated CEM/ErbB4 cells with 10 nM NRG2a, NRG2b, or the five putative loss-of-function NRG2b mutants. Cells treated with 10 nM NRG1b served as a positive control. We assayed ErbB4 tyrosine phosphorylation by ErbB4 immunoprecipitation and antiphosphotyrosine immunoblotting (Figure 3a , top panel). As a control for ErbB4 expression levels, we stripped the blot and probed it with an anti-ErbB4 antibody ( Figure 3a , bottom panel). Both NRG1b and NRG2b stimulate abundant ErbB4 tyrosine phosphorylation, whereas NRG2a does not. Four of the five NRG2b mutants (Q43L, M47P, N49R, and F50L) stimulate abundant ErbB4 tyrosine phosphorylation, but the NRG2b F45K mutant fails to stimulate ErbB4 tyrosine phosphorylation strongly. Thus, Phe45 appears to be necessary for stimulation of ErbB4 tyrosine phosphorylation by NRG2b.
To further characterize the NRG2b F45K mutant we performed dose-response experiments using CEM/ ErbB4 cells. We stimulated CEM/ErbB4 cells with varying amounts of NRG2b and NRG2b F45K. In parallel, we constructed an ErbB4 tyrosine phosphorylation standard curve by analysing varying amounts of ErbB4 immunoprecipitates generated from CEM/ErbB4 cells that had been stimulated with NRG1b. In multiple independent experiments, wild-type NRG2b displayed an average ErbB4 tyrosine phosphorylation EC 50 of 7.071.0 nM (Figure 3b ). The NRG2b F45K mutant is a much less potent ErbB4 agonist, displaying an average ErbB4 tyrosine phosphorylation EC 50 of 90715 nM over multiple experiments (Figure 3c ).
The maximal amount of ErbB4 tyrosine phosphorylation (ErbB4 S max ) stimulated by wild-type NRG2b is 114717% of the ErbB4 S max stimulated by NRG1b (Figure 3b ). The ErbB4 S max stimulated by the NRG2b F45K mutant is 120710% of the ErbB4 S max stimulated by NRG1b (Figure 3c) . Thus, at saturation, wildtype NRG2b and the NRG2b F45K mutant display similar efficacy. Altogether, the results of the doseresponse experiments suggest that Phe45 regulates activation of ErbB4 tyrosine phosphorylation by NRG2b by regulating the affinity of NRG2b for ErbB4.
The NRG2a K45F mutant is a more potent ErbB4 agonist than NRG2a
We then stimulated CEM/ErbB4 cells with the six putative gain-of-function NRG2a mutants at a final concentration of 10 nM. Cells stimulated with 10 nM NRG2a, NRG2b, or NRG1b served as controls. We assayed ErbB4 tyrosine phosphorylation by ErbB4 immunoprecipitation and antiphosphotyrosine immu- Figure 1 The carboxyl terminus and activity of six NRG isoforms. The carboxyl-terminal amino-acid sequence of six NRG isoforms (NRG1a, NRG1b, NRG2a, NRG2b, NRG3, and NRG4) is given. Activation of ErbB4 tyrosine phosphorylation by the six NRG isoforms is indicated Plowman et al., 1993; Tzahar et al., 1994; Carraway et al., 1997; Chang et al., 1997; Zhang et al., 1997; Harari et al., 1999; Hobbs et al., 2002) . Five NRG residues appear to correlate with activation of ErbB4 tyrosine phosphorylation: Gln43, Phe45, Met47, Ser49, and Phe50. Solid underlining indicates identity with this sequence. Dotted underlining indicates conservation with this sequence Figure 2 Putative loss-of-function NRG2b mutants and putative gain-of-function NRG2a mutants. Five NRG2b mutants were constructed by replacing one of the five 'critical' amino acids in NRG2b with the corresponding amino acids of NRG2a. Five NRG2a mutants were constructed by replacing one of the five 'critical' amino acids of NRG2a with the corresponding amino acid of NRG2b. An additional NRG2a mutant, NRG2a Chg5, was constructed by replacing all of the five 'critical' amino acids with the corresponding amino acids of NRG2b. Shaded text indicates the mutated amino acid ErbB4 activation by NRG2 SS Hobbs et al noblotting ( Figure 4a , top panel). As a control for ErbB4 expression levels, we stripped the blot and probed it with an anti-ErbB4 antibody ( Figure 4a , bottom panel). NRG2a and four of the NRG2a mutants (L43Q, P47M, R49N, and L50F) stimulated much less ErbB4 tyrosine phosphorylation than did NRG1b and NRG2b. In contrast, the NRG2a Chg5 and K45F mutants stimulated at least modest amounts of ErbB4 tyrosine phosphorylation. This suggests that Phe45 of NRG2b is sufficient to enable NRG2a to stimulate ErbB4 tyrosine phosphorylation. However, because the NRG2a Chg5 mutant stimulates a greater amount of ErbB4 tyrosine phosphorylation than does the NRG2a K45F mutant, the Gln43, Met47, Asn49, and Phe50 residues may contribute to activation of ErbB4 by NRG2b, despite the fact that none of these residues are individually necessary for activation of ErbB4 by NRG2b or sufficient for activation of ErbB4 by NRG2a.
To further characterize the activity of the NRG2a Chg5 and K45F gain-of-function mutants, we performed dose-response experiments using CEM/ErbB4 cells and methodologies analogous to those described earlier in this report. Over multiple experiments, we failed to stimulate a saturated amount of ErbB4 tyrosine phosphorylation using wild-type NRG2a (Figure 4b ). However, we conservatively estimate that NRG2a exhibits an average ErbB4 tyrosine phosphorylation EC 50 of greater than 300 nM (Figure 4b ). In contrast, the NRG2a K45F (Figure 4b ) and NRG2a Chg5 (Figure 4c ) mutants are much more potent. The average ErbB4 tyrosine phosphorylation EC 50 values for these mutants are 7377 and 3979 nM, respectively.
Over multiple experiments, the average maximal amount of ErbB4 tyrosine phosphorylation (ErbB4 S max ) stimulated by the NRG2a Chg5 mutant is 141723% of the ErbB4 S max stimulated by NRG1b. However, the ErbB4 S max stimulated by the NRG2a K45F mutant is only 7777% of the ErbB4 S max stimulated by NRG1b. Because of the limited potency of wild-type NRG2a, we are not able to determine the ErbB4 S max for that ligand.
The lower ErbB4 tyrosine phosphorylation EC 50 values of the NRG2a K45F and Chg5 mutants relative to NRG2a may reflect a higher affinity of these mutants for ErbB4. This suggests that the Phe45 residue plays an important role in conferring high-affinity binding to ErbB4. The ErbB4 tyrosine phosphorylation EC 50 value Figure 3 Phenylalanine 45 is necessary for stimulation of ErbB4 tyrosine phosphorylation by NRG2. CEM/ErbB4 cells were stimulated with the NRGs and NRG mutants as indicated. ErbB4 tyrosine phosphorylation (anti-pY IB) and expression (anti-ErbB4 IB) were analysed by immunoblotting following ErbB4 immunoprecipitation. Tyrosine phosphorylated ErbB4 is represented by the single band that has slightly greater mobility than the 204 kDa marker. On the ErbB4 blots, ErbB4 is present as a higher molecular weight band that represents the fully processed, mature form of the receptor and a lower molecular weight band that represents the immature form of the receptor. of the NRG2a Chg5 mutant is somewhat lower than that of the NRG2a K45F mutant. This may reflect an increased affinity of NRG2a Chg5 for ErbB4 compared to the affinity of NRG2a K45F for ErbB4. Thus, it appears that the Gln43, Met47, Asn49, and Phe50 residues also play a limited role in regulating the affinity of NRG molecules for ErbB4. The ErbB4 S max stimulated by the NRG2a Chg5 mutant is higher than the ErbB4 S max stimulated by the NRG2a K45F mutant. This suggests that there is an intrinsic difference between the two gain-of-function NRG2a mutants that is independent of their apparent differences in potency or affinity for ErbB4. Again, this highlights the potential role that the Gln43, Met47, Asn49, and Phe50 residues play in defining the function of NRG molecules.
Phe45 is not critical for NRG2-induced coupling of EGFR-ErbB4 heterodimers to IL3 independence
We have previously shown that in the IL3-dependent BaF3 mouse lymphoid cell line, ectopic EGFR and ErbB4 coexpression permits ligands for either EGFR or ErbB4 to stimulate EGFR-ErbB4 heterodimerization and coupling to interleukin-3 (IL3)-independent proliferation (Riese et al., 1995 (Riese et al., , 1996a . In BaF3/ EGFR þ ErbB4 cells, 10 nM of NRG1b, NRG2b or the NRG2a Chg5 mutant all stimulate IL3-independent proliferation, whereas 10 nM NRG2a stimulates, at best, a modest level of IL3 independence ( Figure 5 ). Thus, NRG2a is a much weaker stimulus of EGFR and ErbB4 coupling to downstream signaling events than are NRG1b, NRG2b, and the NRG2a Chg5 mutant. These results are consistent with the ErbB4 tyrosine phosphorylation data shown earlier (Figures 3a and 4a) .
At a concentration of 10 nM, the NRG2a K45F mutant, which stimulates slightly less ErbB4 tyrosine phosphorylation than does 10 nM NRG2a Chg5 in CEM/ErbB4 cells (Figure 4a ), stimulates only modest (at best) IL3 independence in the BaF3/EGFR þ ErbB4 cell line. This may be because the NRG2a K45F mutant is less potent or has a lower affinity for ErbB4 than the NRG2a Chg5 mutant. The other possibility is that there is an intrinsic difference between these two gain-offunction NRG2a mutants that is independent of their apparent differences in potency or affinity for ErbB4. To distinguish between these two possibilities, we assayed IL3 independence in BaF3/EGFR þ ErbB4 cells treated with 73 nM NRG2a K45F, which is the ErbB4 tyrosine phosphorylation EC 50 in CEM/ErbB4 cells. However, this NRG2a K45F concentration still fails to stimulate Figure 4 Phenylalanine 45 is sufficient for stimulation of ErbB4 tyrosine phosphorylation by NRG2. CEM/ErbB4 cells were stimulated with the NRGs and NRG mutants as indicated. ErbB4 tyrosine phosphorylation (anti-pY IB) and expression (anti-ErbB4 IB) were analysed by immunoblotting following ErbB4 immunoprecipitation. Tyrosine-phosphorylated ErbB4 is represented by the single band that has slightly greater mobility than the 204 kDa marker. The blot was stripped and reprobed with an anti-ErbB4 antibody (IB: anti-ErbB4). On the ErbB4 blots, ErbB4 is present as a higher molecular weight band that represents the fully processed, mature form of the receptor and a lower molecular weight band that represents the immature form of the receptor. IL3-independent proliferation in the BaF3/EGFR þ ErbB4 cell line (data not shown). In contrast, 10 nM of the NRG2a Chg5 mutant, a concentration that is much less than the ErbB4 tyrosine phosphorylation EC 50 in CEM/ErbB4 cells, stimulates IL3-independent proliferation ( Figure 5 ). These results are consistent with the differences between the ErbB4 S max values for the NRG2a K45F and Chg5 mutants and provide additional support for our hypothesis that there is an intrinsic difference between the two gain-of-function NRG2a mutants that is independent of their apparent differences in potency or affinity for ErbB4. At a concentration of 10 nM, the NRG2b F45K mutant stimulates IL3-independent proliferation in the BaF3/EGFR þ ErbB4 cells ( Figure 5 ). It must be noted, however, that the NRG2b F45K mutant stimulates a lower level of IL3-independent proliferation than does an equal concentration of wild-type NRG2b. At a concentration of 10 nM, the NRG2b F45K stimulates much less ErbB4 tyrosine phosphorylation in the CEM/ ErbB4 cell line than does wild-type NRG2b (Figure 3a) . Indeed, the dose-response data shown earlier in this report ( Figure 3c ) suggest that the NRG2b F45K mutant has a lower affinity for ErbB4 than does wildtype NRG2b. Consistent with such a model, the NRG2b F45K mutant at a final concentration of 90 nM stimulates a level of IL3-independent proliferation in the BaF3/EGFR þ ErbB4 cell line comparable to the level stimulated by 10 nM wild-type NRG2b (data not shown).
NRG2a gain-of-function mutants stimulate modest EGFR and ErbB4 tyrosine phosphorylation in the BaF3/ EGFR þ ErbB4 cell line
The failure of the NRG2a K45F mutant to stimulate IL3-independent proliferation in the BaF3/ EGFR þ ErbB4 cell line ( Figure 5 ) is not consistent with the ability of the NRG2a K45F mutant to stimulate ErbB4 tyrosine phosphorylation in the CEM/ErbB4 cell line (Figure 4a, b) . Indeed, the NRG2a Chg5 mutant stimulates ErbB4 phosphorylation in the CEM/ErbB4 cell line (Figure 4a , c) and also stimulates IL3-independent proliferation in BaF3/EGFR þ ErbB4 cells ( Figure 5) . A simple possible explanation is that the NRG2a K45F mutant stimulates less ErbB receptor tyrosine phosphorylation in the BaF3/EGFR þ ErbB4 cell line than does the NRG2a Chg5 mutant. Thus, we examined EGFR and ErbB4 tyrosine phosphorylation in BaF3/EGFR þ ErbB4 cells following stimulation with NRG1b, NRG2b, NRG2a K45F, and NRG2a Chg5. We used 10 nM of each ligand except NRG2a K45F, which was used at 73 nM. We used these concentrations of the NRG2a mutants because we had previously shown that 10 nM NRG2a Chg5 stimulates IL3-independent proliferation in the BaF3/EGFR þ ErbB4 cell line ( Figure 5 ), whereas 73 nM NRG2a K45F does not (data not shown).
As shown in Figure 6a , NRG1b stimulates abundant EGFR and ErbB4 tyrosine phosphorylation in the BaF3/EGFR þ ErbB4 cells. NRG2b stimulates a modest amount of EGFR tyrosine phosphorylation and stimulates abundant ErbB4 phosphorylation in the BaF3/EGFR þ ErbB4 cells. NRG2a K45F and NRG2a Chg5 both stimulate modest EGFR and ErbB4 tyrosine phosphorylation in the BaF3/EGFR þ ErbB4 cells. Indeed, despite the fact that the NRG2a Chg5 mutant stimulates IL3-independent proliferation of the BaF3/ EGFR þ ErbB4 cell line and the NRG2a K45F mutant does not, the two NRG2a mutants stimulate similar levels of ErbB receptor tyrosine phosphorylation in the BaF3/EGFR þ ErbB4 cell line. Thus, ligand-induced EGFR and ErbB4 tyrosine phosphorylation does not completely correlate with ligand-induced coupling of EGFR and ErbB4 to IL3-independent proliferation; EGFR and ErbB4 tyrosine phosphorylation is necessary, but does not appear to be sufficient, to couple EGFR and ErbB4 to IL3 independence.
Preliminary results similar to those shown in Figure 6a raised concerns that perhaps our NRG2a K45F stock had degraded and that this accounted for the failure of the NRG2a K45F mutant to stimulate IL3-independent proliferation and abundant ErbB receptor tyrosine phosphorylation in the BaF3/EGFR þ ErbB4 cell line. So, in parallel with the stimulations of the BaF3/ EGFR þ ErbB4 cells shown in Figure 6a , we also stimulated CEM/ErbB4 cells. The ligand concentrations used were identical to those used to stimulate the BaF3/ ErbB4 cells. At a final concentration of 73 nM, the Figure 5 NRG2b F45K and NRG2a Chg5 mutants, but not the NRG2a K45F mutant, stimulate coupling of EGFR and ErbB4 to IL3-independent proliferation in the BaF3/EGFR þ ErbB4 cell line. BaF3/EGFR þ ErbB4 cells were cultured to saturation density, then seeded in 24-well dishes at a density of 100 Â 10 3 cells/ml in media devoid of IL3 but supplemented with 10 nM of the NRGs or NRG mutants as indicated. Mock stimulated cells (Mock) were seeded in medium devoid of IL3 but supplemented with phosphatebuffered saline (NRG diluent). The positive control (IL3) cells were treated with medium containing IL3. After 4 days, the cells were stained with Trypan blue and the density of viable cells was determined by counting viable cells using a hemacytometer NRG2a K45F mutant stimulates a greater amount of ErbB4 tyrosine phosphorylation in the CEM/ErbB4 cell line than did 10 nM of the NRG2a Chg5 mutant (Figure 6b ). This is despite the fact that the NRG2a K45F mutant at a final concentration of 73 nM and the NRG2a Chg5 mutant at a final concentration of 10 nM stimulate similar levels of ErbB receptor tyrosine phosphorylation in the BaF3/EGFR þ ErbB4 cell line. These data indicate that the NRG2a K45F stock was not degraded, and they again suggest that there may be intrinsic differences between the two NRG2a gainof-function mutants apart from the relatively slight difference in potency (affinity for ErbB4).
Discussion
Phe45 regulates NRG2b potency
The NRG2b F45K mutant fails to stimulate ErbB4 tyrosine phosphorylation (Figure 3a) , whereas the NRG2a K45F mutant stimulates abundant ErbB4 tyrosine phosphorylation (Figure 4a ). These data suggest that Phe45 is necessary and sufficient for NRG2 stimulation of ErbB4 tyrosine phosphorylation.
One model for the interactions of EGF family hormones with ErbB family receptors features the binding of a single EGF family hormone to a single ErbB family receptor. Two hormone-receptor complexes then associate to form a heterotetrameric complex of two hormone molecules and two receptor molecules (Sherrill and Kyte, 1996; Lemmon et al., 1997; Domagala et al., 2000) . The receptor molecules phosphorylate each other (either within or between receptor dimers) and the phosphorylated receptors serve as docking sites for downstream signaling molecules that contain SH2 or PTB domains (Sherrill, 1997; reviewed in Weiss and Schlessinger, 1998; Schlessinger, 2000) . Thus, one explanation for the NRG2b F45K loss-offunction mutant and the NRG2a K45F gain-of-function mutant is that Phe45 appears to be part of one of the putative ErbB4 binding sites on NRG2 (Figure 7 ) and could thereby regulate the affinity of NRG2-ErbB4 interactions. This explanation is consistent with several published observations. NRG1b Tyr48 (which corresponds to Phe45 of NRG2b) is conserved when a library of randomly generated NRG1b mutants is screened for those that retain high affinity for ErbB3 and for ErbB4 . Substitution of an alanine for Arg45 of EGF (which corresponds to Phe45 of NRG2b) results in a marked increase in the ligand affinity for the chicken EGF receptor (van de Poll et al., 1995) . As determined by two-dimensional 1 H NMR, the carboxyl-terminal tails of both EGF and TGFa are flexible in solution (Kline et al., 1990; Kohda and Inagaki, 1992) . However, Figure 6 NRG2a gain-of-function mutants stimulate modest EGFR and ErbB4 tyrosine phosphorylation in BaF3/EGFR þ ErbB4 cells. (a) EGFR and ErbB4 tyrosine phosphorylation in BaF3/EGFR þ ErbB4 cells were assayed following stimulation with 10 nM of ligand as indicated except for NRG2a K45F, which was at a concentration of 73 nM. EGFR was immunoprecipitated with an anti-EGFR antibody and ErbB4 was immunoprecipitated with an anti-ErbB4 antibody. EGFR and ErbB4 tyrosine phosphorylation was detected by antiphosphotyrosine immunoblotting. (b) ErbB4 tyrosine phosphorylation in CEM/ErbB4 cells was assayed following stimulation with 10 nM of ligand except for NRG2a K45F, which was a concentration of 73 nM. ErbB4 was immunoprecipitated with an anti-ErbB4 antibody and ErbB tyrosine phosphorylation was detected by antiphosphotyrosine immunoblotting Figure 7 Phe45 of NRG2b may interact with Leu437 and Lys438 of ErbB4. A molecular model of the interaction between Phe45 of NRG2b and ErbB4 was generated using the data from the recently published crystal structure of EGF in complex with EGFR (Ogiso et al., 2002 (Hoyt et al., 1994) . Finally, scanning alanine mutagenesis of NRG1b reveals that substitution of an alanine for Tyr48 causes a greater than twofold loss of affinity for ErbB4 . Thus, these published data are consistent with our observation that the NRG2a K45F mutant is a more potent ligand (with respect to stimulation of ErbB4 tyrosine phosphorylation) than is wild-type NRG2a and that the NRG2b F45K mutant is a less potent ligand than is wild-type NRG2b. Of course, direct evaluation of this hypothesis awaits the determination of the affinities of these NRGs and NRG mutants for ErbB4.
Gln43, Met47, Asn49, and Phe50 regulate NRG2b efficacy
The NRG2a and NRG2b mutants in which amino-acid residues 43, 47, 49, and 50 are individually changed are not significantly different from wild-type NRG2a and NRG2b with respect to their ability to stimulate ErbB4 tyrosine phosphorylation (Figures 3a and 4a) . However, the NRG2a Chg5 mutant, which has residues 43, 45, 47, 49, and 50 changed, is functionally distinct from the NRG2a K45F mutant, in which only residue 45 is changed. This suggests that Gln43, Met47, Asn49, and Phe50 of NRG2b regulate stimulation of ErbB4 signaling by NRG2b. The maximal level of ErbB4 tyrosine phosphorylation that is stimulated by the NRG2a Chg5 mutant is similar to, and perhaps greater than, the level stimulated by NRG2b (Figure 4c ). In contrast, the maximal level of ErbB4 tyrosine phosphorylation that is stimulated by the NRG2a K45F mutant is approximately 30% less than the level stimulated by NRG2b. Furthermore, the maximal level of tyrosine phosphorylation that is stimulated by the NRG2b F45K mutant is equal to the amount that is stimulated by wild-type NRG2b, despite the fact that the NRG2b F45K mutant is a much less potent stimulus of ErbB4 tyrosine phosphorylation than is wild-type NRG2b. Thus, the potency and perhaps the affinity of NRG2 isoforms and NRG2 mutants are regulated by Phe45. In contrast, the efficacy of NRG2 isoforms and NRG2 mutants appear to be regulated by Gln43, Met47, Asn49, and Phe50 or by some combination of these residues.
Further evidence for the contribution of NRG2b amino acids Gln43, Met47, Asn49, and Phe50 to ligandinduced ErbB4 signaling is revealed in IL3-independence assays using BaF3/EGFR þ ErbB4 cells. NRG2b, which stimulates abundant ErbB4 tyrosine phosphorylation, also stimulates IL3-independent proliferation in BaF3/EGFR þ ErbB4 cells. In contrast, NRG2a K45F, even at concentrations that stimulate abundant ErbB4 tyrosine phosphorylation in CEM/ErbB4 cells (Figure 6b ), does not stimulate IL3-independent proliferation in BaF3/EGFR þ ErbB4 cells ( Figure 5 ). This indicates that Phe45 is not sufficient for complete stimulation of ErbB4 signaling by NRG2a. Furthermore, the NRG2a Chg5 and NRG2b F45K mutants stimulate IL3-independent proliferation, indicating Gln43, Met47, Asn49, and Phe50 are critical for complete stimulation of ErbB4 signaling by NRG2. Again, these data indicate that the efficacy of NRG2 isoforms and NRG2 mutants appear to be regulated by Gln43, Met47, Asn49, and Phe50 or by some combination of these residues.
It is tempting to speculate on the mechanism by which Gln43, Met47, Asn49, and Phe50 regulate the efficacy of NRG2 isoforms and mutants. One possibility is suggested by the observation that wild-type NRG2b and the NRG2a Chg5 and NRG2b F45K mutants all stimulate similar levels of maximal ErbB4 tyrosine phosphorylation. In contrast, the NRG2a K45F mutant stimulates a lower level of maximal ErbB4 phosphorylation than these other ligands. This suggests that different numbers of ErbB4 tyrosine residues are being phosphorylated in response to NRG2a K45F stimulation than in response to stimulation with wild-type NRG2b, the NRG2b F45K mutant, and the NRG2a Chg5 mutant.
There are precedents in the literature for this type of differential signaling. We have reported that the ErbB4 ligand NRG4, unlike NRG2b or NRG3, does not stimulate IL3 independence in BaF3/EGFR þ ErbB4 cells. This indicates that NRG4, unlike NRG2b and NRG3, fails to stimulate the phosphorylation of ErbB4 tyrosine residues that couple to IL3 independence (Hobbs et al., 2002) . These data also suggest that different signaling molecules will be coupled to ErbB4 following stimulation with different ErbB4 ligands. Indeed, stimulation of CEM/ErbB4 cells with BTC, NRG1b, NRG2b, or NRG3 caused differential phosphorylation of downstream signaling molecules such as Akt and Erk1/2. In addition, stimulation of CEM/ ErbB4 cells with these ligands caused differential coupling of ErbB4 to Shc and p85. Finally, the different ligands also stimulated phosphorylation of different tyrosine residues on ErbB4. These data indicate that an ErbB4 homodimer can indeed differentially signal depending on the identity of the stimulating ligand (Sweeney et al., 2000) .
Of course, we then must speculate on the mechanism by which different ligands can cause ErbB4 to become phosphorylated on different tyrosine residues. We propose the different ligands cause ErbB4 to undergo subtly different conformation changes, resulting in receptor dimers or multimers in which different ErbB4 tyrosine residues are juxtaposed with the ErbB4 kinase domain. Thus, different ligands cause ErbB4 to become phosphorylated on different tyrosine residues.
Several published studies provide support for this model. The structures of liganded and partially liganded EGFR demonstrate that significant structural changes occur in the ectodomain of EGFR when EGFR is bound by either TGFa or EGF. The ectodomain of EGFR is made up of four subdomains, designated as L1, CR1, L2, and CR2. The L1 and L2 domains contain the ligand binding sites on EGFR. The CR1 domain functions as the 'dimerization arm' that links two EGFR molecules together. The CR2 domain may function as an inhibitor of receptor dimerization in unliganded EGFR by binding the 'dimerization arm' in a manner that prevents the dimerization arm of one EGFR molecule from binding the dimerization arm of another EGFR molecule (Ogiso et al., 2002) . In the partially liganded EGFR crystal structure, in which EGF is bound only to the L1 domain, the L1 and L2 domains are separated by a large distance and the ligand-binding sites of the domains are pointed in the opposite direction. In fact, for the L1-bound EGF to bind to the binding sites on the L2 domain, as seen in the liganded EGFR crystal structure, the L1/CR1 domain rigid body has to rotate 1301 clockwise and translate 20 Å toward the L2 domain. This large movement disrupts the interaction between domains CR1 and CR2, which frees the CR1 domain to facilitate receptor dimerization (Ferguson et al., 2003) .
It has been proposed that the EGFR exists in a dynamic equilibrium between a closed conformation and an open conformation. EGF receptors in the closed conformation, which is characterized by CR1 and CR2 interactions, bind ligands with very low affinity and are incapable of undergoing dimerization. EGF receptors in the open conformation, which is characterized by the absence of CR1/CR2 interactions, bind ligands with high affinity and are capable of undergoing dimerization and signaling. In this model, ligand binds only to those receptors in the open conformation and shifts the dynamic equilibrium in favor of the open conformation, thereby stabilizing these receptors in the conformation suitable for dimerization and signaling (Ferguson et al., 2003) .
These data illustrate that in order for ligands to bind ErbBs, large conformational changes in the ErbB structure have to occur. These conformational changes may include conformational changes in the cytoplasmic domains of the ErbBs, which may influence the identity of the tyrosine residues on the cytoplasmic tail that are phosphorylated in response to ligand binding. The crystal structure of TGFa in complex with EGFR indicates that almost 60% of the amino acids in TGFa are in contact with EGFR (Garrett et al., 2002) . As a result, it is certainly possible that the conformational changes in ErbB4 that accompany ligand binding may be influenced by the three-dimensional structure of the ligands that bind to the receptor.
The primary sequence of EGF-like ligands and the solved, three-dimensional structures of a couple of ligands indicate a great deal of structural similarity among the EGF-like ligands. A comparison of the crystal structures of EGF (bound to EGFR) and betacellulin (in the absence of EGFR) shows that these ligands share a great deal of similarity in secondary structure; however, there are tertiary differences between the ligands that may influence how they interact with ErbBs (Garrett et al., 2002; Miura et al., 2002) . For instance, EGF has a number of residues that fill in the cavity formed by the closing of ligand binding domains of EGFR. Betacellulin, on the hand, is nearly flat on this face of the ligand that faces toward the dimerization domain of EGFR. This difference may influence the type of conformational changes that EGFR can undergo upon ligand binding.
One explanation for differential phosphorylation of ErbB4 is that each of the ligands somehow causes a conformational change in ErbB4 that causes different tyrosine residues on the cytoplasmic tail of one ErbB4 molecule to be juxtaposed to the kinase domain of another ErbB4 molecule. These proximal tyrosine residues are then tyrosine phosphorylated by the ErbB4 partner.
Of course, such an explanation is dependent upon conformation changes in the ErbB4 extracellular domains being translated to conformation changes in the ErbB4 intracellular domains. A number of experiments indicate that this transfer of structural information across the cell membrane does indeed occur.
Substitution of a single cysteine at several different sites in the juxtamembrane, extracellular region of ErbB2 results in ErbB2 mutants that display elevated, constitutive ErbB2 tyrosine phosphorylation. However, only a subset of these biochemically constitutively active mutants were capable of causing morphologic growth transformation of cultured rodent fibroblast cell lines. Indeed, only cysteine substitutions that occurred on a specific face of the a-helical juxtamembrane domain of ErbB2 resulted in mutants competent for transforming the growth of FR3T3 fibroblasts. This indicates that only those phosphorylated tyrosine residues that align with this face of the a-helical juxtamembrane domain are capable of coupling to growth transformation. Thus, the coupling of ErbB2 tyrosine phosphorylation to downstream biological and biochemical events is specified by the juxtapositioning (conformation) of the ErbB2 monomers within the ErbB2 dimer (Burke and Stern, 1998) .
Similar results have been reported for ErbB4. The substitution of a cysteine for Gln646, His647, and Ala648 in the extracellular, juxtamembrane region of ErbB4 results in constitutive, ligand-independent ErbB4 tyrosine phosphorylation. However, the ErbB4 Q646C mutant displays less ErbB4 tyrosine phosphorylation than do the ErbB4 H647C or A648C mutants (Penington et al., 2002) . Nonetheless, only the Q646C mutant inhibited drug-resistant colony formation by human DU-145 and PC-3 prostate tumor cell lines. This indicates that the Q646C mutant is phosphorylated on a set of ErbB4 tyrosine residues distinct from those sets of ErbB4 tyrosine residues phosphorylated in the H647C and A648C mutants (Williams et al., 2003) . Parenthetically, unpublished data from our laboratory suggest that Tyr1056 is the site of Q646C-specific ErbB4 tyrosine phosphorylation that couples to prostate tumor suppression. In any event, these published and unpublished data indicate that differential conformation changes in the extracellular domains of ErbB family receptors can indeed be translated into differential ErbB receptor tyrosine phosphorylation and support our hypothesis that different EGF family hormones differentially activate ErbB receptor signaling through differential induction of ErbB receptor conformation changes.
In sum, then, we predict that the major role that Phe45 plays in regulating NRG2b function is to confer high-affinity ErbB4 binding upon NRG2b. Moreover, we predict that when the NRG2a Chg5 mutant, wildtype NRG2b, or the NRG2b F45K mutant binds to ErbB4, the Gln43, Met47, Asn49, and Phe50 residues participate in inducing a conformational change in ErbB4 that is different from the conformational change in ErbB4 induced by the corresponding four residues of wild-type NRG2a or the NRG2a K45F mutant. The differential ErbB4 conformational change induced by NRG2a Chg5, wild-type NRG2b, or the NRG2b F45K mutant causes different tyrosine residues on ErbB4 to be phosphorylated compared to the ErbB4 tyrosine residues whose phosphorylation is stimulated by the binding of wild-type NRG2a or the NRG2a K45F mutant to ErbB4. Naturally, these predictions await ErbB4-binding studies, structural studies of the interactions between ErbB4 and NRGs or NRG mutants, as well as detailed phosphopeptide mapping of ErbB4 following its stimulation with the NRGs and NRG mutants.
Materials and methods
Cell lines and cell culture
The S2 Schneider insect cells were purchased from the American Type Culture Collection. The CEM/ErbB4 cells Riese et al., 1998) are a generous gift of Dr Gregory D Plowman, Exelixis Pharmaceuticals. The BaF3/EGFR þ ErbB4 cell lines have been described previously (Riese et al., 1995) . All cell lines were maintained according to vendor instructions or published procedures Riese et al., 1995; Feroz et al., 2002; Hobbs et al., 2002) .
Construction of NRG2a and NRG2b mutants
The five putative loss-of-function mutants of NRG2b were constructed by 'four-primer' PCR using two flanking primers (used to construct all of the mutants), two mutagenic primers (a different set for each mutant) and the pMT-NRG2b clone (Hobbs et al., 2002) as template. The amplified DNA fragments were cleaved using BglII and SacII and were subcloned into the BglII and SacII sites of pMT/BiP/V5-HisB.
The forward flanking primer used to make all of the mutants is 5 0 -CTCGAGAGATCTTCGGGGCACGCCCGGAAGTG-3 0 . The reverse flanking primer used to make all of the mutants is 5 0 -CTCGAGCCGCGGCTTCTGGTACAGCTCCTC-3 0 . The forward mutagenic primer used to make the NRG2b Q43L mutant is 5 0 -GGGGACAGGTGTCTGCAGTTCGCAATG-3 0 . The reverse mutagenic primer used to make the NRG2b Q43L mutant is the complement. The forward mutagenic primer used to make the NRG2b F45K mutant is 5 0 -CAGGTGTCAGCAGAAGGCAATGGTCAAC-3 0 . The reverse mutagenic primer used to make the NRG2b F45K mutant is the complement. The forward mutagenic primer used to make the NRG2b M47P mutant is 5 0 -CAGCAGTTCG-CACCGGTCAACTTCTCC-3 0 . The reverse mutagenic primer used to make the NRG2b M47P mutant is the complement. The forward mutagenic primer used to make the NRG2b N49R mutant is 5 0 -GTTCGCAATGGTCCGCTTCTCCAA-GCAC-3 0 . The reverse mutagenic primer used to make the NRG2b N49R mutant is the complement. The forward mutagenic primer used to make the NRG2b F50L mutant is 5 0 -CGCAATGGTCAACTTGTCCAAGCACCTTG-3 0 . The reverse mutagenic primer used to make the NRG2b F50L mutant is the complement.
The six putative gain-of-function mutants of NRG2a were generated using the QuikChange site-directed mutagenesis kit (Stratagene). The forward mutagenic primer used to make the NRG2a L43Q mutant is 5 0 -GTCCAAACGGATTCTTTG-GCCAGAGATGTCAGGA GAAACTGCCTTTGCG-3 0 . The reverse mutagenic primer used to make the NRG2a L43Q mutant is the complement. The forward mutagenic primer used to make the NRG2a K45F mutant is 5 0 -CCAAA-CGGATTCTTTGGCCAGAGATGTTTGGAGTTCCTGC-CTTTGCGATTG-3 0 . The reverse mutagenic primer used to make the NRG2a K45F mutant is the complement. The forward mutagenic primer used to make the NRG2a P47M mutant is 5 0 -GTTTGGAGAAACTGATGTTGCGATTATA-CATGCCAGATCC-3 0 . The reverse mutagenic primer used to make the NRG2a P47 M mutant is the complement. The forward mutagenic primer used to make the NRG2a R49N mutant is 5 0 -GGAGAAACTGCCTTTGAACTTATA-CATGCCAGATCC-3 0 . The reverse mutagenic primer used to make the NRG2a R49N mutant is the complement. The forward mutagenic primer used to make the NRG2a L50F mutant is 5 0 -GCCTTTGCGATTCTACATGCCAGATC-3 0 . The reverse mutagenic primer used to make the NRG2a L50F mutant is the complement. The forward mutagenic primer used to make the NRG2a Chg5 mutant is 5 0 -CGGACAGAGATGTCAGGAGTTCCTGATGTTGAACT-TCTACATGCCAGATC-3 0 . The reverse mutagenic primer used to make the NRG2a Chg5 mutant is the complement.
Expression, purification, and quantification of recombinant NRGs and NRG mutants
The insect cell expression plasmid pMT/BiP/V5-HisB (Invitrogen) contains a Drosophila metallothionein promoter as well as segments encoding the BiP secretion signal, a V5 epitope tag, and a hexahistidine epitope tag. We have previously described the construction of the recombinant NRG2a and NRG2b insect cell expression vectors based on pMT/BiP/V5-HisB (Hobbs et al., 2002) .
We have previously described our strategy for expressing and purifying the recombinant NRGs and NRG mutants (Hobbs et al., 2002) . Briefly, S2 cells were co-transfected with 19 mg of the appropriate recombinant pMT-NRG plasmid and 1 mg pCoHygro (Invitrogen), which expresses the hygromycin resistance gene. Cells were transferred to medium containing 300 mg/ml hygromycin B (Calbiochem) to select for stable transformants, which were pooled and expanded into stable cell lines.
The stably transfected S2 cell lines were seeded in serum-free insect cell culture medium supplemented with 1 mM CuSO 4 to induce NRG expression. Cells were incubated for 5 days to permit maximal NRG expression and secretion into the culture medium. The cell culture conditioned medium was cleared and was concentrated by ultrafiltration. The retentate was dialysed against phosphate-buffered normal saline (PBS). The NRG was purified from the concentrated crude protein preparation by affinity chromatography using a nickel ion matrix (ProBond. -Invitrogen). The NRG was eluted from the nickel ion matrix using 500 mM imidazole (Sigma). The eluate was concentrated by ultrafiltration and the retentate was dialysed against PBS to remove the imidazole. The purified protein (B4 ml) was divided into aliquots and stored at À801C.
Anti-V5 immunoblotting was used to quantify the concentrations of the recombinant NRG samples (Hobbs et al., 2002) . Briefly, NRG samples were resolved by SDS-PAGE and were electroblotted onto nitrocellulose. The blots were probed using an anti-V5 mouse monoclonal antibody (Invitrogen). The Positope recombinant protein (Invitrogen) was analysed in parallel as a control for V5 immunoblotting and as a standard for quantification. The resulting immunoblots were digitized at 600 dots-per-inch (d.p.i.) using a UMAX Astra 2400S flatbed scanner and the bands were quantified using NIH Image for Macintosh software. We generated dose-response curves of best fit for the Positope control and for each recombinant NRG using Microsoft Excel. These curves were used to calculate the concentration of each recombinant NRG stock.
The concentration of each NRG preparation was determined relative to the concentration of the NRG2b preparation by ELISA using an anti-V5 monoclonal antibody (Invitrogen) (Hobbs et al., 2002) . Briefly, the levels of antibody binding were plotted as a function of sample stock volume for NRG2a and the NRG2 mutants. These dose-response curves were compared to a standard dose-response curve generated using NRG2b to determine the relative concentration of the NRG stocks.
Stimulation and analysis of ErbB family receptor tyrosine phosphorylation
We analysed ligand-induced ErbB family receptor tyrosine phosphorylation in CEM/ErbB4 and BaF3/EGFR þ ErbB4 cells by antiphosphotyrosine immunoblotting using procedures published previously (Riese et al., 1995 (Riese et al., , 1996a (Riese et al., , b, 1998 Chang et al., 1997; Feroz et al., 2002; Hobbs et al., 2002) . Briefly, approximately 10 7 cells were stimulated for 7 min on ice with ligand, after which the cells were lysed in an isotonic lysis buffer supplemented with the nonionic detergent NP40. Nuclei and debris were collected from the lysates by centrifugation and the supernatants were transferred to a fresh tube. The protein content of the lysates was analysed using a modified Bradford assay (Pierce). ErbB family receptors were precipitated from the lysates using an anti-EGFR mouse monoclonal antibody (Santa Cruz Biotechnology) or an anti-ErbB4 rabbit polyclonal antibody (Santa Cruz Biotechnology).
The precipitates were resolved by SDS-PAGE using a 7.5% acrylamide gel. For several of the immunoblots, varying amounts of tyrosine phosphorylated ErbB4 immunoprecipitates were used as controls. We generated these controls by stimulating four aliquots of 10 7 CEM/ErbB4 cells with 10 nM NRG1b. We immunoprecipitated ErbB4 from each aliquot, eluted the ErbB4 from the immunocomplexes, and pooled the eluates. Typically, eluate volumes corresponding to 200, 100, 50, and 25% of a standard stimulation (10 7 CEM/ErbB4 cells) were loaded onto the gels to serve as controls.
The resolved samples were electroblotted onto nitrocellulose. The blots were probed using an antiphosphotyrosine mouse monoclonal antibody (Upstate Biotechnology). Primary antibody binding was detected using a goat anti-mouse antibody conjugated to horseradish peroxidase (Pierce). Secondary antibody binding was visualized by chemiluminescence (Amersham).
The chemilumigrams were digitized at 600 d.p.i. using a UMAX Astra 2400S flatbed scanner and the volumes of the bands were quantified using NIH Image software for Macintosh. From the CEM/ErbB4 immunoblots, ErbB4 phosphotyrosine standard curves were constructed from the NRG1b load-response data using Microsoft Excel. The maximal level of ErbB4 tyrosine phosphorylation (ErbB4 S max ) that is stimulated by each ligand was calculated using the ErbB4 tyrosine phosphorylation load-response standard curve generated in Microsoft Excel. The resulting values are expressed as a percentage of ErbB4 tyrosine phosphorylation stimulated by NRG1b. In Figures 3 and 4 , the load-response standard curves were used to calculate relative levels of maximal ErbB4 tyrosine phosphorylation that are stimulated by NRG2a, NRG2b, and the NRG2 mutants. The resulting data are expressed as a percentage of ErbB4 tyrosine phosphorylation stimulated by NRG1b. We also analysed ErbB4 tyrosine phosphorylation following stimulation of CEM/ErbB4 cells with increasing concentrations of NRG2a, NRG2b, and the NRG2 mutants. These dose-response data were analysed with the GraphPad Prism 3.0 software for Macintosh to determine the concentration of each ligand that yields half-maximal ErbB4 tyrosine phosphorylation (EC 50 ).
Stimulation and analysis of ErbB family receptor coupling to IL3 independence
We have previously demonstrated that certain combinations of tyrosine phosphorylated ErbB family receptors couple to IL3-independent survival and/or proliferation in the IL3-dependent BaF3 lymphoid cell line (Riese et al., 1995 (Riese et al., , 1996a . Thus, we analysed the NRG2 mutants for ligand-induced ErbB family receptor coupling to IL3 independence in BaF3/ EGFR þ ErbB4 cells using procedures published previously (Riese et al., 1995 (Riese et al., , 1996a (Riese et al., , b, 1998 Chang et al., 1997; Hobbs et al., 2002) . Briefly, cells were seeded in 24-well dishes at a density of 10 5 cells/ml in medium lacking IL3, in medium supplemented with IL3, or in media lacking IL3 but supplemented with 10 nM of a recombinant NRG. Cells were incubated for 96 h, after which viable cells were counted using a hemacytometer. If the viable cell density was greater than 10 5 cells/ml, the cells were judged to be proliferating. If the viable cell density was between 10 4 and 10 5 cells/ml, the cells were judged to be surviving. If the viable cells density was below 10 4 cells/ml, the cells were judged to be dying.
Generation of a molecular model for the interaction between NRG2b and ErbB4
The X-ray crystal structure coordinates of EGF in complex with EGFR were obtained from the Protein Data Bank (Accession Number 1IVO). These data were manipulated using the Sybyl 6.9 software (Tripos) on a Silicon Graphics O2 workstation. Amino acids Tyr44 through Glu51 of EGF were mutated to the corresponding amino acids (Gln44 through Ser51) of NRG2b. In addition, amino acids Ala439 through Gly446 of EGFR were mutated to the corresponding amino acids (Leu435 through Gln442) of ErbB4. Finally, a subset energy minimization was performed using the MMFF94s force field equation on a 'hot' region defined as being within 6 Å or less away from the mutated region and on an 'interesting' region defined as being between 6 and 12 Å away from the mutated region. In the energy minimizations, the atomic coordinates are changed over a number of iterations to minimize the free energy of the region. Atoms within the 'hot' region are fully minimized, whereas atoms within the 'interesting' region are only partially minimized (Halgren, 1999) .
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